secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0001641172-25-005078
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.02, 2.02, 5.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant completes secondary sale of 73.1M shares (52.5% stake) from OrbiMed to Nantahala; Q1 rev guidance $32.8-33.1M
--------------------------------------------------------------------------------

- OrbiMed affiliates sold 73.1M shares (52.5% of outstanding) to Nantahala-led group at $0.42/share; OrbiMed now holds no Xtant shares.
- Nantahala now owns 49.1% of Xtant (68.4M shares), becoming the largest stockholder and gaining effective control.
- Investor rights agreement with OrbiMed terminated; company gains strategic and operational flexibility.
- Preliminary Q1 2025 revenue expected $32.8M-$33.1M, up 18-19% YoY driven by orthobiologics and licensing.
- Company loses NYSE American controlled company status; now must comply with independent director and committee rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000164117225005078/0001641172-25-005078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000164117225005078/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer